Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The analysis of the financial leverage and debt ratios over the periods reveals a generally stable to slightly improving capital structure with some fluctuations in recent quarters.
- Debt to equity ratio
- The debt to equity ratio demonstrates a declining trend from 1.16 in the first quarter of 2021 to a lower range around 0.66 to 0.87 during 2022 and early 2023, indicating a reduction in relative debt levels compared to equity. However, there is a noticeable increase in 2023 where the ratio rises to 0.95 in the second quarter, followed by fluctuations between 0.85 and 0.93 towards the end of 2023 and into 2024. The ratio slightly decreases again in the subsequent quarters, stabilizing around 0.72 to 0.80 by mid to late 2025, suggesting moderate variability but overall controlled leverage.
- Debt to capital ratio
- This ratio follows a similar pattern to the debt to equity ratio but with less volatility, indicating that debt composes roughly 40% to 54% of the capital structure across the examined periods. Initial values decrease from 0.54 in early 2021 to about 0.40 by late 2022, reflecting reduced reliance on debt financing. A slight uptick is observed in 2023 with a peak near 0.49, followed by modest oscillations around 0.44 to 0.46 through 2024 and 2025. Overall, the proportion of debt in the capital structure remains moderate without extreme shifts.
- Debt to assets ratio
- The debt to assets ratio maintains a moderate level between 0.28 and 0.34 over the period. The ratio trends downward slightly from 0.34 at the start of 2021 to a range near 0.28 in late 2021 and much of 2022, denoting a small improvement in asset coverage relative to debt. An increase occurs in the first half of 2023 reaching 0.35, followed by a return to approximately 0.30 to 0.32 in subsequent quarters. This pattern indicates some variation in asset and debt base but overall a conservative and consistent asset financing structure.
- Financial leverage ratio
- Financial leverage, measured as the ratio of total assets to equity, declines from 3.37 in early 2021 to around 2.3 to 2.7 during 2022 and 2023, suggesting a reduction in the extent to which equity finances assets relative to liabilities. Although there are slight increases and decreases during the quarterly periods of 2023 and 2024, the ratio remains generally stable within the range of approximately 2.3 to 2.8. Toward the end of 2025, the leverage ratio settles near 2.5, indicating a moderately leveraged financial position with steady risk exposure.
In summary, the financial ratios indicate a prudent approach to leveraging throughout the reported periods, with debt levels maintained at moderate proportions relative to equity, capital, and assets. Some short-term fluctuations appear during 2023, but these do not significantly alter the overall conservative leverage posture. The company’s capital structure reflects controlled debt usage, supporting financial stability while allowing flexibility for future financing needs.
Debt Ratios
Debt to Equity
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Loans payable and current portion of long-term debt | |||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to equity = Total debt ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals notable dynamics in both total debt and stockholders’ equity over multiple quarters. Total debt exhibits fluctuations, with periods of rising and falling levels, indicating varying leverage strategies or refinancing activities during the analyzed timeframe. On the other hand, total stockholders’ equity generally demonstrates a growing trend over the long term, reflecting potential accumulation of retained earnings, equity issuances, or valuation changes.
- Total Debt
- The total debt figures show initial volatility, with decreases observed early in the period, followed by intermittent increases. The debt level peaked around mid-2023 and again showed elevation towards the end of the timeline. This pattern suggests episodic borrowing, repayment activities, or shifts in capital structure policy.
- Total Stockholders’ Equity
- Stockholders’ equity broadly increased over time, indicating a progressive strengthening of the company’s financial foundation. Despite occasional declines in some quarters, the overall trajectory suggests positive retained earnings momentum or equity capital infusions, which contribute to the company’s net asset base.
- Debt to Equity Ratio
- This ratio fluctuates significantly across the periods, initially declining from above one to below one, pointing to reduced leverage or equity growth outpacing debt. A notable spike around mid-2023 implies increased debt relative to equity, possibly reflecting heightened borrowing. Subsequent periods show the ratio stabilizing below one, indicating a moderate leverage position. The overall pattern suggests a cautious approach to leveraging, balancing debt utilization with equity growth to maintain financial stability.
In summary, the company appears to manage its capital structure actively, with strategic borrowings and equity growth shaping the debt-to-equity balance. The increasing stockholders’ equity alongside variable debt levels indicate a strengthening financial base with careful leverage management throughout the quarters analyzed.
Debt to Capital
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Loans payable and current portion of long-term debt | |||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals notable fluctuations and trends in the debt and capital structure over the observed periods. Total debt in US dollars exhibits variability, with initial amounts around 31,253 million decreasing to approximately 26,441 million by the third quarter of 2021, followed by intermittent increases and decreases. Starting from the first quarter of 2023, total debt shows a rising trend again, reaching the highest recorded value of 41,374 million in the third quarter of 2025.
Total capital also demonstrates a general upward trend. Beginning near 58,198 million, total capital rises steadily through most quarters, peaking at 93,224 million in the third quarter of 2025. There are periods of slower growth or slight declines, particularly around the end of 2023, yet the overall trajectory over the examined timeframe is positive.
The debt to capital ratio reflects the interplay between total debt and total capital. Initially high at 0.54 in the first quarter of 2021, the ratio declines through mid-2022 to about 0.40, indicating a reduction in leverage or improved capital base relative to debt. However, from early 2023 onwards, the ratio climbs to values fluctuating between 0.42 and 0.49, suggesting a moderate increase in leverage. Notably, the peak ratio of 0.49 in the second quarter of 2023 marks a significant point of increased debt proportion relative to capital, followed by a mild reduction and stabilization around 0.44 in the later periods.
The overall observations indicate a company managing its capital structure with varying degrees of debt levels and capital accumulation. While total capital grows consistently over the long term, total debt portrays periods of both reduction and escalation, impacting leverage ratios accordingly. This dynamic suggests active financial management strategies possibly responsive to market conditions or company-specific investment and financing decisions.
- Total Debt
- Fluctuates with an initial decline followed by a general upward trend from early 2023 to late 2025, peaking at 41,374 million.
- Total Capital
- Shows a steady increase throughout the periods, rising from 58,198 million to 93,224 million, with minor short-term fluctuations.
- Debt to Capital Ratio
- Decreases from 0.54 to around 0.40 by mid-2022, then rises again, peaking near 0.49 in mid-2023, before stabilizing around 0.44 towards late 2025.
Debt to Assets
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Loans payable and current portion of long-term debt | |||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals distinct trends in the company's leverage and asset base over the observed periods.
- Total Debt
- The total debt levels show fluctuations with an overall upward tendency in the later periods. Initially, there was a decline from approximately 31.3 billion USD in the first quarter of 2021 down to about 26.5 billion USD in the second quarter of 2021. This was followed by periods of volatility with debt values oscillating around the 30 billion USD mark through the end of 2022. Commencing in early 2023, debt consistently increased, reaching a peak of approximately 41.4 billion USD by the third quarter of 2025, marking a significant rise compared to prior periods.
- Total Assets
- Total assets demonstrated a generally growing trend with some minor fluctuations. Beginning near 90.8 billion USD in the first quarter of 2021, assets increased to over 105 billion USD by the end of 2021. The asset base remained relatively stable around 106 to 109 billion USD through 2022, followed by an expansion starting in 2023. By the third quarter of 2025, total assets reached approximately 129.5 billion USD, indicating a substantial growth in the asset base across the timeframe.
- Debt to Assets Ratio
- The debt-to-assets ratio exhibits moderate variability but remains confined within a relatively narrow range, suggesting controlled leverage in relation to asset growth. Initially at 0.34 in the first quarter of 2021, this ratio decreased to a low near 0.28 by the end of 2021 and maintained similar levels through 2022. Beginning in early 2023, the ratio increased, peaking around 0.35 in the second quarter of 2023, before stabilizing near 0.30 to 0.32 in the following quarters through to the third quarter of 2025. This pattern indicates that debt increases were generally in line with asset growth, maintaining a balanced leverage position over time.
In summary, the company has expanded its asset base significantly while managing debt growth at a somewhat controlled pace. The debt-to-assets ratio remains consistent with prudent leverage management despite the upward trend in nominal debt values. This suggests an approach balancing growth and financial risk prudently over the analyzed quarters.
Financial Leverage
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends regarding the company's asset structure, equity position, and leverage over the observed periods.
- Total Assets
- The total assets display a general upward trend from March 31, 2021, through to September 30, 2025, increasing from approximately 90.8 billion US dollars to about 129.5 billion US dollars. There are some fluctuations within this trend; for instance, a modest decline occurred between March 31, 2023, and June 30, 2023, followed by a recovery and further growth in subsequent quarters. Overall, the steady increase indicates ongoing asset accumulation and a growth in the company’s resource base.
- Total Stockholders’ Equity
- Stockholders’ equity similarly exhibits growth from around 26.9 billion US dollars in the first quarter of 2021 to approximately 51.9 billion US dollars by the third quarter of 2025. However, the equity trend contains more volatility compared to total assets. Notably, equity surged until December 31, 2022, but then experienced a significant decline in the first quarter of 2023. This decline was followed by alternating periods of increase and decrease, indicating possible fluctuations due to earnings variability, equity transactions, or other comprehensive income adjustments. Despite these variations, the equity balance trends upward over the long term, suggesting positive value creation for shareholders.
- Financial Leverage
- The financial leverage ratio, calculated as total assets divided by stockholders’ equity, shows a general decrease from 3.37 in March 2021 to around 2.5 in September 2025, indicating a reduction in reliance on debt relative to equity. The ratio demonstrates oscillations, such as spikes around the end of 2023 and less leverage in some quarters of 2022 and 2024. These movements suggest periods of changing capital structure management, where the company may have adjusted debt levels or equity through financing activities. The downward trend in leverage suggests an overall strategy towards a more balanced or equity-oriented capital structure over time.